Education
About Us
Working with TipRanks
Follow Us
Concord Biotech Ltd. (IN:CONCORDBIO)
:CONCORDBIO
CONCORDBIO Stock Chart & Stats
₹1338.60
₹62.10(2.74%)
At close: 4:00 PM EST
₹1338.60
₹62.10(2.74%)
Day’s Range― - ―
52-Week Range₹1,081.00 - ₹2,149.90
Previous CloseN/A
Volume295.44K
Average Volume (3M)12.81K
Market Cap
₹120.24B
Enterprise Value₹114.85B
Total Cash (Recent Filing)₹3.18B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)38.5
Beta1.20
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)6.30
Shares Outstanding104,616,200
10 Day Avg. Volume31,605
30 Day Avg. Volume12,808
Financial Highlights & Ratios
PEG Ratio2.27
Price to Book (P/B)9.60
Price to Sales (P/S)14.50
P/FCF Ratio127.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA low-leverage balance sheet gives Concord durable financial flexibility: it can fund capacity expansion, withstand regulatory or demand cycles, and access capital on favorable terms without pressuring cash flows. This strengthens long-term resilience and strategic optionality.
Cash GenerationConsistent, growing operating cash flow supports ongoing investment in fermentation capacity and process development, funds working capital, and reduces refinancing risk. Strong cash conversion from profits underpins durable operations and funds strategic initiatives without overreliance on external financing.
Profitability And Revenue TrendSustained revenue growth and healthy margins reflect efficient manufacturing and pricing power in complex fermentation-based APIs. Consistent profitability supports reinvestment, and indicates durable competitive advantages in making difficult-to-manufacture molecules for specialty therapeutic areas.
Bears Say
Free Cash Flow & Margin PressureInconsistent free cash flow growth and weakening gross margin create medium-term constraints on capital allocation. They can limit steady funding for capacity upgrades or R&D, increase sensitivity to input-cost shocks, and reduce the company’s ability to pursue opportunistic investments or absorb demand swings.
Customer / Product ConcentrationReliance on a limited set of customers or key molecules raises revenue volatility and bargaining-power risk. Loss or repricing of a major contract could underutilize specialized fermentation assets, harming utilization-led margins and making long-term cash flows more sensitive to individual counterparty actions.
Earnings Per Share TrendNegative EPS growth signals earnings pressure despite revenue gains, suggesting margin compression, cost inflation, or one-off impacts. Persistent EPS decline would weaken retained-earnings growth and limit options for shareholder returns or reinvestment, affecting long-term capital allocation flexibility.
Concord Biotech Ltd. News
CONCORDBIO FAQ
What was Concord Biotech Ltd.’s price range in the past 12 months?
Concord Biotech Ltd. lowest stock price was ₹1081.00 and its highest was ₹2149.90 in the past 12 months.
What is Concord Biotech Ltd.’s market cap?
Concord Biotech Ltd.’s market cap is ₹120.24B.
When is Concord Biotech Ltd.’s upcoming earnings report date?
Concord Biotech Ltd.’s upcoming earnings report date is May 21, 2026 which is in 85 days.
How were Concord Biotech Ltd.’s earnings last quarter?
Concord Biotech Ltd. released its earnings results on Feb 11, 2026. The company reported ₹6.3 earnings per share for the quarter, missing the consensus estimate of ₹7.2 by -₹0.9.
Is Concord Biotech Ltd. overvalued?
According to Wall Street analysts Concord Biotech Ltd.’s price is currently Overvalued.
Does Concord Biotech Ltd. pay dividends?
Concord Biotech Ltd. pays a Notavailable dividend of ₹10.7 which represents an annual dividend yield of 0.8%. See more information on Concord Biotech Ltd. dividends here
What is Concord Biotech Ltd.’s EPS estimate?
Concord Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Biotech Ltd. have?
Concord Biotech Ltd. has 104,616,200 shares outstanding.
What happened to Concord Biotech Ltd.’s price movement after its last earnings report?
Concord Biotech Ltd. reported an EPS of ₹6.3 in its last earnings report, missing expectations of ₹7.2. Following the earnings report the stock price went down -3.042%.
Which hedge fund is a major shareholder of Concord Biotech Ltd.?
Currently, no hedge funds are holding shares in IN:CONCORDBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Concord Biotech Ltd.
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Technical Analysis
Biocon Limited
―
Blue Jet Healthcare Limited
―
Jubilant Ingrevia Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―